Skip to content
ClinCalc Pro
Menu
Antiparasitic / Antifungal — PCP Prophylaxis / Treatment / Malaria

Atovaquone

Brand names: Wellvone, Malarone (combined with proguanil)

Atovaquone is an oral antiprotozoal and antifungal agent used mainly for the treatment and prevention of Pneumocystis jirovecii pneumonia in patients who cannot tolerate co-trimoxazole, and for toxoplasmosis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits the parasite cytochrome bc1 complex of the mitochondrial electron transport chain, disrupting pyrimidine biosynthesis and energy production.

Prescribing in practice

  • Absorption is poor and highly dependent on fat, so atovaquone must be taken with a fatty meal to achieve adequate plasma concentrations and treatment efficacy, particularly important in patients with diarrhoea or malabsorption.
  • It is generally less effective than co-trimoxazole for Pneumocystis pneumonia, so it is reserved for those intolerant of first-line therapy.
  • Concurrent rifampicin and certain other agents can substantially lower atovaquone levels and reduce efficacy.

Monitoring

Monitor clinical response and tolerability, with attention to whether the drug is being taken with food to ensure adequate absorption.

Counselling the patient

  • Always take this medicine with food, ideally something containing fat, to help it work.
  • Continue prophylaxis for as long as advised even when you feel well.
  • Report persistent diarrhoea or vomiting, which may reduce how well the drug is absorbed.

Evidence & guidelines

Atovaquone is recommended in UK guidance as an alternative agent for Pneumocystis jirovecii pneumonia prophylaxis and treatment in patients intolerant of co-trimoxazole.

Reference: BHIVA HIV Guidelines; PHE Malaria Guidelines; NICE Malaria Prevention Guidance; IDSA PCP Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.